Boosting a certain brain protein could help slow the progression of Alzheimer’s disease, a new study has found. The ...

New research suggests that the lessening of amyloid-beta in the brain is behind cognitive decline in Alzheimer's and boosting ...

Leqembi and Kisunla don’t just reduce amyloid plaques that are implicated in Alzheimer’s disease. According to new research, ...

A study published in the journal Brain shows that increases in protein levels with new Alzheimer's drugs can explain the ...

A study shows that rising levels of brain protein Aβ42, not the reduction of amyloid plaques, better explains the cognitive ...

"Aβ42 is a protein that defends our brain from a variety of toxic and infectious exposures," Espay said. "In the process of reacting, it transforms into amyloid plaques. Amyloid plaques is made of ...

Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been ...

However, while the level of Aβ42 in blood is not by itself a good biomarker for AD, the Aβ42:Aβ40 ratio has gained attention as a plasma biomarker that predicts amyloid-PET status regardless of ...

Meta-analysis of two studies showed that levels of Aβ42 in plasma were slighlty higher in people with progressive supranuclear palsy than people with Alzheimer's disease (effect size = 1.16). However, ...

Caffeine and Alzheimer disease risk appear to be linked, as lower caffeine intake is associated with Alzheimer disease biomarkers.

Three months after treatment with troculeucel, two patients in the Phase I portion went from having moderate to mild symptoms of dementia.

A new study published in the journal Brain reveals that increasing levels of a key brain protein might help slow cognitive ...